Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by sammie88on Mar 05, 2020 9:51am

86 Views

Post# 30769769

RE:Timing

Good morning folks,

We are all forgetting that the world is still deeply entrentched in the Coronavirus; and it is most likely to get worse before it gets better.

Personally I'm not surprised by these low stock prices at all. I doubt we will hear anything from Replicel until the virus shows signs of slowing down.

These fluctuations, and even potentially lower stock price is to be expected.

Regards,
Sammie

(Solely my personal opinion)

Bullboard Posts

How one company is disrupting PoC testing